| Activation of blood coagulation via clotting cascade |
F3, ANO6 |
2 |
2 |
Inf |
0.000574 |
Up |
| Antigen processing and presentation of exogenous peptide antigen |
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G, NCF2, PSMB8, PSMB9, PSMD5, TAP1, IFI30 |
165 |
22 |
6.58 |
6.84e-11 |
Up |
| Antigen processing and presentation of exogenous peptide antigen via MHC class I |
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, NCF2, PSMB8, PSMB9, PSMD5, TAP1, IFI30 |
75 |
14 |
9.66 |
2.45e-09 |
Up |
| Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent |
CTSS, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G |
9 |
6 |
82.7 |
1.45e-08 |
Up |
| Antigen processing and presentation of exogenous peptide antigen via MHC class II |
CTSS, FCER1G, HLA-DMA, HLA-DMB, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, IFI30 |
92 |
11 |
5.66 |
1.24e-05 |
Up |
| Antigen processing and presentation of peptide antigen via MHC class I |
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, NCF2, PSMB8, PSMB9, PSMD5, TAP1, IFI30 |
97 |
14 |
7.09 |
7.58e-08 |
Up |
| Apoptotic process |
AHR, APOE, FAS, BCL2A1, BCL6, BMP2, BTK, CAMK2D, CASP1, CASP4, TNFSF8, CDKN1A, CTSC, DAB2, NQO1, ECT2, EDN1, F3, FCER1G, HCK, HGF, HIF1A, HMOX1, ICAM1, IFI16, IL1A, ITGA5, JAK3, LMNB1, LYN, MNDA, MYC, NCF2, NOS3, P2RX4, PLAGL1, PLAUR, PLSCR1, PRLR, PSMB8, PSMB9, PSMD5, PTPN2, CCL2, CCL19, SNAI2, STAT1, TEK, TGFB2, TLR2, TLR3, GPR65, YBX3, NOL3, SOCS3, LY86, IKBKE, CHL1, PPP1R15A, RRM2B, SHISA5, TNFRSF12A, ACSL5, FNIP2, DNASE2B, ZMAT3, NOA1, FGD3, IL33, DEDD2, ANO6 |
1745 |
71 |
1.89 |
5.22e-06 |
Up |
| Apoptotic signaling pathway |
FAS, BCL2A1, BTK, CASP4, CDKN1A, CTSC, ECT2, HGF, HIF1A, HMOX1, ICAM1, IFI16, IL1A, NOS3, P2RX4, PLAUR, PTPN2, SNAI2, TGFB2, TLR3, YBX3, NOL3, IKBKE, PPP1R15A, RRM2B, SHISA5, TNFRSF12A, ACSL5, FNIP2, FGD3, IL33, DEDD2 |
596 |
32 |
2.43 |
1.88e-05 |
Up |
| Axonemal dynein complex assembly |
DNAH5, DNAI1, TEKT2, ZMYND10, ARMC4, DNAH7, CCDC114, CCDC151, DNAAF1, CCDC39 |
21 |
10 |
175 |
8.54e-18 |
Down |
| Axoneme |
DNAH5, DNAH9, SPAG6, DNAI1, DCDC2, HYDIN, CFAP46, ARMC4, MNS1, DNAH7, CFAP74, CCDC114, CCDC151, DNAAF1, CFAP54, DNAH2, SPAG17, CFAP221, CCDC39, RSPH4A |
89 |
20 |
52.5 |
1.31e-25 |
Down |
| Axoneme assembly |
DNAH5, DNAI1, TEKT2, ZMYND10, HYDIN, CFAP46, ARMC4, DNAH7, CFAP74, RSPH1, CCDC114, CCDC151, DNAAF1, SPAG17, CCDC39, RSPH4A |
42 |
16 |
128 |
5.9e-26 |
Down |
| B cell mediated immunity |
FAS, BCL6, BTK, C1QB, C1QC, C7, FCER1G, HLA-DMA, HLA-DQB1, HLA-DRB1, HLA-DRB5, CFI, IL4R, CD226, TLR8 |
103 |
15 |
7.18 |
2.28e-08 |
Up |
| Cellular protein modification process |
IL12RB1, INS, KCNE1, MAK, CFP, RASA4, TRAK2, MYLK3, NEK5, C17orf97, PPIAL4A |
3527 |
11 |
0.473 |
0.00885 |
Down |
| Cellular response to interferon-gamma |
CAMK2D, EDN1, FCGR1A, GBP1, HCK, HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G, ICAM1, IRF8, OAS2, PTPN2, CCL2, CCL19, STAT1, SOCS3, IFI30, TRIM38, TRIM5 |
126 |
27 |
11.9 |
1.95e-18 |
Up |
| Clathrin-coated endocytic vesicle membrane |
FCGR1A, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5 |
49 |
7 |
7.32 |
0.000108 |
Up |
| Copper ion import |
ATP7B, SLC31A1, STEAP4 |
7 |
3 |
30.7 |
0.000446 |
Up |
| Cytokine production involved in immune response |
BCL6, BTK, FCER1G, HLA-A, HMOX1, JAK3, SLC11A1, TEK, TGFB2, TLR2, TLR3, TREM1 |
69 |
12 |
8,81 |
7,87E-08 |
Up |
| Endolysosome membrane |
TLR3, TLR7, TLR8 |
4 |
3 |
131 |
4.51e-05 |
Up |
| Fc receptor mediated stimulatory signaling pathway |
FCER1G, FCGR1A, FCGR2A, FGR, HCK, ITPR3, LYN, PLSCR1, CD226, MYO1G |
77 |
10 |
6.21 |
1.47e-05 |
Up |
| Humoral immune response mediated by circulating immunoglobulin |
C1QB, C1QC, C7, HLA-DQB1, HLA-DRB1, HLA-DRB5, CFI |
46 |
7 |
7.42 |
0.000103 |
Up |
| Igg binding |
FCER1G, FCGR1A, FCGR2A, FCGR2B |
10 |
4 |
28.3 |
5.42e-05 |
Up |
| Immunoglobulin production |
FAS, BCL6, CD37, HLA-DQB1, HLA-DRB1, HLA-DRB5, IL4R, TNFSF13B, POLM, IL33 |
87 |
10 |
5.4 |
4.34e-05 |
Up |
| Inner dynein arm assembly |
TEKT2, ZMYND10, DNAH7, DNAAF1, CCDC39 |
10 |
5 |
182 |
1.44e-09 |
Down |
| Integral component of lumenal side of endoplasmic reticulum membrane |
HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G |
28 |
11 |
28.8 |
1.04e-11 |
Up |
| Interferon-alpha production |
TLR3, NMI, TLR7, TLR8 |
18 |
4 |
11.7 |
0.000764 |
Up |
| Interferon-beta biosynthetic process |
TLR3, NMI, TLR7, TLR8 |
8 |
4 |
41.1 |
2.12e-05 |
Up |
| Interferon-gamma biosynthetic process |
TLR3, EBI3, TLR7, TLR8 |
16 |
4 |
13.7 |
0.000472 |
Up |
| Interleukin-10 production |
FCER1G, HLA-DRB1, HLA-DRB5, JAK3, TLR2, PDCD1LG2 |
42 |
6 |
6.87 |
0.000463 |
Up |
| Intrinsic apoptotic signaling pathway |
BCL2A1, CASP4, CDKN1A, HIF1A, HMOX1, IFI16, PLAUR, PTPN2, SNAI2, YBX3, NOL3, IKBKE, PPP1R15A, RRM2B, SHISA5, FNIP2 |
284 |
16 |
2.49 |
0.00143 |
Up |
| Macrophage activation |
IL4R, SLC11A1, TLR1, SBNO2, CD93, TLR7, TLR8, IL33 |
48 |
8 |
8.29 |
1.66e-05 |
Up |
| Mast cell cytokine production |
BCL6, FCER1G, HMOX1 |
7 |
3 |
30.7 |
0.000446 |
Up |
| MHC class II receptor activity |
HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1 |
11 |
5 |
35.4 |
2.73e-06 |
Up |
| MHC protein complex |
HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G |
25 |
13 |
48.4 |
1.34e-15 |
Up |
| Microtubule bundle formation |
DNAH5, DNAI1, TEKT2, ZMYND10, HYDIN, CFAP46, ARMC4, DNAH7, CFAP74, RSPH1, CCDC114, CCDC151, DNAAF1, SPAG17, CCDC39, RSPH4A |
63 |
16 |
70.7 |
1.18e-22 |
Down |
| Monocyte chemotaxis |
CCR1, LYN, CCL2, CCL19, PLA2G7, ANO6 |
49 |
6 |
5.75 |
0.00107 |
Up |
| Outer dynein arm assembly |
DNAH5, DNAI1, ZMYND10, ARMC4, CCDC114, CCDC151, DNAAF1 |
11 |
7 |
325 |
5.6e-14 |
Down |
| Peptide antigen binding |
HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G, TAP1 |
26 |
10 |
26.9 |
1.57e-10 |
Up |
| Platelet-derived growth factor receptor binding |
TYMP, ITGA5, ITGB3, LYN |
12 |
4 |
21.2 |
0.000123 |
Up |
| Positive regulation of Fc receptor mediated stimulatory signaling pathway |
LYN, CD226 |
2 |
2 |
Inf |
0.000574 |
Up |
| Positive regulation of interleukin-6 production |
FCER1G, TLR1, TLR2, TLR3, TLR7, IL33 |
55 |
6 |
5.05 |
0.00197 |
Up |
| Positive regulation of interleukin-8 production |
TLR2, TLR3, TLR5, TLR7, TLR8 |
42 |
5 |
5.56 |
0.00318 |
Up |
| Positive regulation of tumor necrosis factor production |
FCER1G, CCL2, CCL19, TLR1, TLR2, TLR3 |
51 |
6 |
5.5 |
0.00133 |
Up |
| Protection from natural killer cell mediated cytotoxicity |
HLA-A, HLA-B, TAP1 |
5 |
3 |
61.5 |
0.000132 |
Up |
| Regulated secretory pathway |
ANXA3, FCER1G, FGR, HCK, HMOX1, IL4R, LYN, STX11, CD300A, RAB11FIP2, RAB11FIP1 |
73 |
11 |
7.4 |
1.23e-06 |
Up |
| Regulation of apoptotic process |
APOE, FAS, BCL2A1, BCL6, BMP2, BTK, CAMK2D, CASP1, CASP4, CDKN1A, CTSC, DAB2, NQO1, ECT2, EDN1, F3, FCER1G, HCK, HGF, HIF1A, HMOX1, ICAM1, IL1A, ITGA5, JAK3, LYN, MNDA, MYC, NCF2, NOS3, PLAUR, PRLR, PSMB8, PSMB9, PSMD5, PTPN2, CCL2, CCL19, SNAI2, STAT1, TEK, TGFB2, TLR3, YBX3, NOL3, SOCS3, CHL1, RRM2B, TNFRSF12A, ACSL5, ZMAT3, FGD3, DEDD2, ANO6 |
1344 |
54 |
1.82 |
0.000117 |
Up |
| Regulation of B cell apoptotic process |
BCL6, BTK, LYN |
16 |
3 |
9.45 |
0.00608 |
Up |
| Regulation of coagulation |
APOE, EDN1, F3, FCER1G, LYN, NOS3, PLAU, PLAUR, THBD, HPSE, ADAMTS18, ANO6 |
85 |
12 |
6.87 |
8.31e-07 |
Up |
| Regulation of cytokine biosynthetic process |
CD86, HMOX1, IL1A, TLR1, TLR2, TLR3, NMI, EBI3, TLR7, TLR8 |
93 |
10 |
5.01 |
7.72e-05 |
Up |
| Regulation of extrinsic apoptotic signaling pathway |
FAS, HMOX1, ICAM1, IL1A, NOS3, SNAI2, TGFB2, NOL3, TNFRSF12A, ACSL5, DEDD2 |
155 |
11 |
3.17 |
0.0013 |
Up |
| Regulation of Fc receptor mediated stimulatory signaling pathway |
LYN, PLSCR1, CD226 |
5 |
3 |
61.5 |
0.000132 |
Up |
| Regulation of hemostasis |
APOE, EDN1, F3, FCER1G, LYN, NOS3, PLAU, PLAUR, THBD, HPSE, ADAMTS18, ANO6 |
81 |
12 |
7.27 |
4.87e-07 |
Up |
| Regulation of leukocyte apoptotic process |
BCL6, BTK, FCER1G, HIF1A, JAK3, LYN, CCL19, TGFB2 |
74 |
8 |
5.02 |
0.000386 |
Up |
| Regulation of lipid kinase activity |
FGR, LYN, CCL19, TEK, NRBF2 |
47 |
5 |
4.89 |
0.0052 |
Up |
| Regulation of mast cell activation |
FCER1G, FGR, HMOX1, IL4R, LYN, PLSCR1, CD226, CD300A |
31 |
8 |
14.4 |
4.96e-07 |
Up |
| Regulation of mast cell degranulation |
FCER1G, FGR, HMOX1, IL4R, LYN, CD300A |
24 |
6 |
13.8 |
1.71e-05 |
Up |
| Regulation of microtubule movement |
DNAH11, ARMC4, DNAAF1, CCDC39 |
18 |
4 |
51.3 |
3.03e-06 |
Down |
| Regulation of natural killer cell mediated immunity |
HLA-A, HLA-B, PVR, TAP1, CD226 |
27 |
5 |
9.36 |
0.000405 |
Up |
| Regulation of protein metabolic process |
FOXJ1, INS, CFP, RASA4, NEK5, DTHD1 |
2448 |
6 |
0.381 |
0.00803 |
Down |
| Regulation of protein modification process |
INS, RASA4 |
1641 |
2 |
0.192 |
0.00288 |
Down |
| Regulation of T-helper 1 cell differentiation |
HLX, IL4R, JAK3, CCL19 |
9 |
4 |
32.9 |
3.74e-05 |
Up |
| T cell costimulation |
CD86, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, LYN, CCL19, TNFSF13B, PDCD1LG2 |
71 |
11 |
7.65 |
9.25e-07 |
Up |
| TAP binding |
HLA-A, HLA-B, HLA-C, HLA-F, TAP1 |
7 |
5 |
106 |
1.34e-07 |
Up |
| T-helper 2 cell differentiation |
BCL6, CD86, HLX, IL4R |
14 |
4 |
16.4 |
0.00027 |
Up |
